Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: Randomized, open-label pilot study

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 2, 2013, Pages 164-170

  Mills, Anthony ^a   Mildvan, Donna ^b   Podzamczer, Daniel ^c   Fätkenheuer, Gerd ^d   Leal, Manuel ^e   Than, Soe ^f   Valluri, Srinivas R ^f   Craig, Charles ^g   McFadyen, Lynn ^g   Vourvahis, Manoli ^f   Heera, Jayvant ^f   Valdez, Hernan ^f   Rinehart, Alex R ^h   Portsmouth, Simon ^f  

^a Anthony Mills MD Inc   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f PFIZER INC   (United States)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^h VIIV HEALTHCARE   (United States)

Author keywords

atazanavir; emtricitabine; HIV 1; maraviroc; ritonavir; tenofovir

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; CREATININE; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; MARAVIROC; VIRUS RNA;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VIRAL TROPISM; VOMITING;

ADENINE; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CYCLOHEXANES; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; ORGANOPHOSPHONATES; PILOT PROJECTS; PYRIDINES; RECEPTORS, CCR5; RITONAVIR; RNA, VIRAL; TRIAZOLES; VIRAL LOAD; YOUNG ADULT;

EID: 84872866264     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31827b51b5     Document Type: Article

References (28)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338: 853-860. (Pubitemid 28135961)
2. Panel onAntiretroviralGuidelines forAdults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2008:1-139. Available at http://www.aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf. Accessed September 27, 2012.
3. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735-1744. (Pubitemid 28454438)
4. Lesho EP, Gey DC. Managing issues related to antiretroviral therapy. Am Fam Physician. 2003;68:675-686.
5. Nolan D, Reiss P, Mallal S. Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin Drug Saf 2005;4:201-218. (Pubitemid 40867334)
6. Food and Drug Administration. Selzentry: highlights of prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2007/022128lbl.pdf. Accessed September 27, 2012.
7. European Medicines Agency. Celsentri (maraviroc), European Public Assessment Report. Available at: http://www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/medicines/000811/human-med-000689.jsp&murl=menus/ medicines/medicines.jsp&mid=WC0b01ac058001d124. Accessed December 14, 2011.
8. Gulick R, Fätkenheuer G, Burnside R, et al. Five-year safety evaluation of maraviroc in HIV-1-infected, treatment-experienced patients. Poster TUPE029. Presented at XIX International AIDS Conference; July 22-27, 2012; Washington, DC.
9. Cooper DA, Heera J, Ive P, et al. Five-year efficacy and safety of maraviroc versus efavirenz, each in combination with zidvudine/lamivudine, in treatment-naive HIV-1-infected patients: open-label extension of the randomized, double-blind MERIT study. Poster TUPE026. Presented at XIX International AIDS Conference; July 22-27, 2012; Washington, DC.
10. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral- naive individuals. J Infect Dis 2005;192:466-474. (Pubitemid 41023125)
11. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis. 2005; 191:866-872. (Pubitemid 40349800)
12. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010;201:803-813.
13. Taylor S, Arribas JR, Perno CF, et al. Efficacy of maraviroc (MVC) administered once daily (QD) or twice (BID) with boosted protease inhibitors (BbPIs) to treatment-experienced patients. Presented at: 6th International AIDS Conference on HIV Pathogenesis, Treatment and Prevention; July17-20, 2011; Rome, Italy.
14. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429-1441.
15. Fätkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359:1442-1455.
16. McFadyen L, Jacqmin P, Wade JR, et al. Maraviroc exposure-efficacy (,50 copies/mL) analysis in HIV-1 infected treatment-naïve subjects - ITT population (MERIT study). Presented at 17th International AIDS Conference; August 3-8, 2008: Mexico City, Mexico.
17. Weatherley B, McFadyen L, Chan PLS, et al. Population pharmacokinetic covariate analysis of maraviroc in Phase 2b/3 studies in treatment experienced (TE) HIV-1 infected subjects on optimized background therapy (OBT). Poster 17a. Presented at 9th International Workshop on Clinical Pharmacology of HIV Therapy; April 7-9, 2008; New Orleans, LA.
18. Le Tiec C, Barrail A, Goujard C, et al. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005;44:1035-1050. (Pubitemid 41356390)
19. RosarioMC, Poland B, Sullivan J, et al. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. J Acquir Immune Defic Syndr. 2006;42:183-191. (Pubitemid 43884713)
20. Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205:1230-1238.
21. Trinh L, Han D, Huang W, et al. Technical validation of an enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Poster presented at XVII International HIV Drug Resistance Workshop; June 10-14, 2008; Sitges, Spain.
22. Weatherley B, Vourvahis M, McFadyen L. Modeling of maraviroc pharmacokinetics in the presence of atazanavir/ritonavir in healthy volunteers and HIV-1-infected patients. Presented at 12th International Workshop on the Clinical Pharmacology of HIV Therapy; April 13-15, 2011; Miami, Florida.
23. Weatherley B, McFadyen L, Chan PLS, et al. Population pharmacokinetic covariate analysis of maraviroc in the MERIT study in treatment naïve subjects. Poster presented at International Workshop on Clinical Pharmacology of HIV Therapy - 9th Annual; April 7-9, 2008: New Orleans, LA.
24. Fätkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11:1170-1172. (Pubitemid 43093663)
25. Kozal MJ, Lupo S, DeJesus E, et al. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatmentnaive HIV-infected patients: SPARTAN study results. HIV Clin Trials. 2012;13:119-130.
26. Reynes J, Lawal A, Pulido F, et al. Lopinavir/ritonavir combined with raltegravir demonstrated similar antiviral efficacy and safety as lopinavir/ ritonavir combined with tenofovir disoproxil fumarate/emtricitabine in treatment-naïve HIV-1 infected subjects. XVIII International AIDS conference; July 18-23, 2010; Vienna, Austria.
27. Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of Darunavir/Ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011;25:2113-2122.
28. Nozza S, Galli L, Antinori A, et al. Maraviroc 150 mg QD plus lopinavir/ritonavir, a NRTIs-sparing regimen for naïve patients: preliminary 48-weeks results. Presented at 6th international AIDS Conference on HIV Pathogenesis, Treatment and Prevention; July 17-20, 2011; Rome, Italy.